RESEARCH TRIANGLE PARK, N.C. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the

RESEARCH TRIANGLE PARK, N.C. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the

RESEARCH TRIANGLE PARK, N.C. --(BUSINESS WIRE)--Jul. 30, 2018-- Liquidia Technologies, Inc. (the “Company”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of

RESEARCH TRIANGLE PARK, N.C. --(BUSINESS WIRE)--Jul. 25, 2018-- Liquidia Technologies, Inc. (the “Company”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT ® technology to transform the lives of

Liquidia Technologies, Inc. , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that it has filed a registration statement on Form S-1

Liquidia Technologies, Inc.  (“Liquidia”), a late-stage clinical biopharmaceutical company focused on improving the performance of medicine by precisely engineering drug particles, today announced the appointment of Jeri Thomas as Senior Vice President, Commercial. Ms.